Expression of CD2, CD25, and/or CD30 is one of the minor criteria set by both the 2022 ICC and the WHO 5th edition, which should always be evaluated by immunohistochemistry and/or flow cytometry. This evidence concerns the gene TNFRSF8 and intrahepatic cholangiocarcinoma.